Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData
January 27, 2012 61 Pages - SKU: GBDT6797306
|
|
Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Gallbladder Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Gallbladder Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gallbladder Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Gallbladder Cancer Therapeutics market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gallbladder Cancer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Gallbladder Cancer Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gallbladder Cancer Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Gallbladder Cancer Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Gallbladder Cancer Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gallbladder Cancer Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Gallbladder Cancer Therapeutics market landscape? - Identify, understand and capitalize.
|
Additional InformationGlobalData, the industry analysis specialist, has released its new report, “Gallbladder Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global gallbladder cancer
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Gallbladder Cancer Therapeutics - Introduction
- 2.1 Overview
- 2.2 Epidemiology
- 2.3 Etiology
- 2.4 Pathophysiology
- 2.5 Signs and Symptoms
- 2.6 Diagnosis
- 2.6.1 Physical exam and history
- 2.6.2 Ultrasound exam
- 2.6.3 Liver function tests
- 2.6.4 Carcinoembryonic antigen (CEA) assay
- 2.6.5 Cancer antigen 19-9 (CA 19-9) assay
- 2.6.6 CT scan (CAT scan)
- 2.6.7 Blood chemistry studies
- 2.6.8 Chest x-ray
- 2.6.9 MRI (magnetic resonance imaging)
- 2.6.10 ERCP (Endoscopic Retrograde Cholangiopancreatography)
- 2.6.11 Biopsy
- 2.6.12 Laparoscopy
- 2.6.13 PTC (Percutaneous Transhepatic Cholangiography)
- 2.7 Staging
- 2.7.1 TNM Classification
- 2.7.2 Treatment Options Based on the Extent of Cancer
- 2.8 Treatment
- 2.8.1 Surgery
- 2.8.2 Chemotherapy
- 2.8.3 Radiation therapy (RT)
- 2.9 Chemotherapy Regimens
- 2.10 GlobalData Pipeline Report Guidance
- 3 Gallbladder Cancer Therapeutics - Market Characterization
- 3.1 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Global
- 3.2 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Global
- 3.3 Gallbladder Cancer Therapeutics Market Size (2005-2010) - US
- 3.4 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - The US
- 3.5 Gallbladder Cancer Therapeutics Market Size (2005-2010) - The UK
- 3.6 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - The UK
- 3.7 Gallbladder Cancer Therapeutics Market Size (2005-2010) - France
- 3.8 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - France
- 3.9 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Germany
- 3.10 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Germany
- 3.11 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Italy
- 3.12 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Italy
- 3.13 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Spain
- 3.14 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Spain
- 3.15 Gallbladder Cancer Therapeutics Market Size (2005-2010) - Japan
- 3.16 Gallbladder Cancer Therapeutics Market Forecast (2010-2018) - Japan
- 3.17 Drivers and Barriers for the Gallbladder Cancer Therapeutics Market
- 3.17.1 Drivers for the Gallbladder Cancer Therapeutics Market
- 3.17.2 Barriers for the Gallbladder Cancer Therapeutics Market
- 3.18 Key Events Impacting the Future Market
- 3.18.1 Opportunity and Unmet Need
- 3.19 Key Takeaway
- 4 Gallbladder Cancer Therapeutics Market - Competitive Assessment
- 4.1 Overview
- 4.1.1 Strategic Competitor Assessment
- 4.2 Profiles of the Commonly Used Products in the Gallbladder Cancer Therapeutics Market
- 4.2.1 Gemcitabine
- 4.2.2 Gemcitabine and Cisplatin
- 4.2.3 Gemcitabine and Oxaliplatin (GEMOX)
- 4.2.4 Gemcitabine and Capecitabine
- 4.2.5 5-Fluorouracil (5-FU) and Cisplatin
- 4.3 Key Takeaway
- 5 Gallbladder Cancer Therapeutics Market - Pipeline Assessment
- 5.1 Overview
- 5.2 Strategic Pipeline Assessment
- 5.3 Gallbladder Cancer Pipeline Analysis - Pipeline by Clinical Phases of Development
- 5.3.1 Gallbladder Cancer Therapeutics - Phase II Pipeline
- 5.3.2 Gallbladder Cancer Therapeutics - Phase I/II Pipeline
- 5.3.3 Gallbladder Cancer Therapeutics - Phase I Pipeline
- 5.4 Gallbladder Cancer Pipeline by Mechanism of Action
- 5.5 Gallbladder Cancer Technology Trends Analytical Framework
- 5.6 Profiles of Phase II Drugs under Clinical Development
- 5.6.1 Caprelsa (vandetanib)
- 5.6.2 Sinofuan (fluorouracil implant)
- 5.7 Key Takeaway
- 6 Gallbladder Cancer Therapeutics - Clinical Trials Mapping
- 6.1 Clinical Trials by Country (US, EU5 and Japan)
- 6.2 Clinical Trials Mapping by Phase
- 6.3 Clinical Trials Mapping by Trial Status
- 6.4 Overall Sponsors
- 6.5 Prominent Sponsors
- 6.6 Top Companies Participating in Gallbladder Cancer Therapeutics Clinical Trials
- 7 Gallbladder Cancer Therapeutics - Strategic Assessment
- 7.1 Future Market Competition Scenario
- 8 Gallbladder Cancer Therapeutics - Future Players in The Market
- 8.1 Introduction
- 8.2 Company Profiles
- 8.2.1 AstraZeneca PLC
- 8.2.2 Simcere Pharmaceutical Co. Ltd.
- 9 Gallbladder Cancer Therapeutics- Appendix
- 9.1 Definitions
- 9.2 Acronyms
- 9.3 Research Methodology
- 9.3.1 Coverage
- 9.3.2 Secondary Research
- 9.3.3 Forecasting
- 9.3.4 Primary Research
- 9.3.5 Expert Panel Validation
- 9.4 Contact Us
- 9.5 Disclaimer
- 9.6 Bibliography
- 1.1 List of Tables
- Table 1: Survival Rates of Gallbladder Cancer in Various Stages
- Table 2: Prevalence of Gallbladder Cancer in Major Markets
- Table 3: Gallbladder Cancer, TNM Definitions
- Table 4: Gallbladder Cancer, Stage Grouping
- Table 5: Treatment Options Based on the Extent of Cancer
- Table 6: Gallbladder Cancer Chemotherapy regimens
- Table 7: Gallbladder Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010
- Table 8: Gallbladder Cancer Therapeutics Market, Global, Forecast ($m), 2010-2018
- Table 9: Gallbladder Cancer Therapeutics Market, The US, Revenue ($m), 2005-2010
- Table 10: Gallbladder Cancer Therapeutics Market, The US, Revenue ($m), 2010-2018
- Table 11: Gallbladder Cancer Therapeutics Market, The UK, Revenue ($m), 2005-2010
- Table 12: Gallbladder Cancer Therapeutics Market, The UK, Forecast ($m), 2010-2018
- Table 13: Gallbladder Cancer Therapeutics Market, France, Revenue ($m), 2005-2010
- Table 14: Gallbladder Cancer Therapeutics Market, France, Forecast ($m), 2010-2018
- Table 15: Gallbladder Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010
- Table 16: Gallbladder Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2018
- Table 17: Gallbladder Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010
- Table 18: Gallbladder Cancer Therapeutics Market, Italy, Forecast ($m), 2010-2018
- Table 19: Gallbladder Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010
- Table 20: Gallbladder Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2018
- Table 21: Gallbladder Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010
- Table 22: Gallbladder Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2018
- Table 23: Gallbladder Cancer - Phase II Pipeline
- Table 24: Gallbladder Cancer Therapeutics - Phase I/II Pipeline
- Table 25: Gallbladder Cancer Therapeutics - Phase I Pipeline
- Table 26: Gallbladder Cancer Therapeutics - Clinical Trials by Country, 2011
- Table 27: Gallbladder Cancer Therapeutics - Clinical Trials by Phase, 2011
- Table 28: Gallbladder Cancer Therapeutics - Clinical Trials by Status, 2011
- Table 29: Gallbladder Cancer Therapeutics - Clinical Trials, by Overall Sponsors, 2011
- Table 30: Gallbladder Cancer Therapeutics - Clinical Trials by Prominent Sponsors, 2011
- Table 31: Gallbladder Cancer Therapeutics Clinical Trial - Company Sponsors by Phase, 2011
- Table 32: AstraZeneca - Gallbladder Cancer Pipeline
- Table 33: Simcere Pharmaceutical - Gallbladder Cancer Pipeline
- 1.2 List of Figures
- Figure 1: Anatomy of the Gallbladder
- Figure 2: Magnetic Resonance Imaging
- Figure 3: Gallbladder Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010
- Figure 4: Gallbladder Cancer Therapeutics, Market Share ($m), 2010
- Figure 5: Gallbladder Cancer Therapeutics Market, Global, Forecast ($m), 2010-2018
- Figure 6: Gallbladder Cancer Therapeutics, Market Share ($m), 2018
- Figure 7: Gallbladder Cancer Therapeutics Market, The US, Revenue ($m), 2005-2010
- Figure 8: Gallbladder Cancer Therapeutics Market, The US, Forecast ($m), 2010-2018
- Figure 9: Gallbladder Cancer Therapeutics Market, The UK, Revenue ($m), 2005-2010
- Figure 10: Gallbladder Cancer Therapeutics, The UK, Forecast ($m), 2010-2018
- Figure 11: Gallbladder Cancer Therapeutics Market, France, Revenue ($m), 2005-2010
- Figure 12: Gallbladder Cancer Therapeutics Market, France, Forecast ($m), 2010-2018
- Figure 13: Gallbladder Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010
- Figure 14: Gallbladder Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2018
- Figure 15: Gallbladder Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010
- Figure 16: Gallbladder Cancer Therapeutics Market, Italy, Forecast ($m), 2010-2018
- Figure 17: Gallbladder Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010
- Figure 18: Gallbladder Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2018
- Figure 19: Gallbladder Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010
- Figure 20: Gallbladder Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2018
- Figure 21: Gallbladder Cancer Therapeutics, Key Events Impacting the Future Market
- Figure 22: Opportunity and Unmet Need in the Gallbladder Cancer Therapeutics Market, 2011
- Figure 23: Gallbladder Cancer Therapeutics Market- Strategic Competitor Assessment, 2011
- Figure 24: Gallbladder Cancer Therapeutics - Pipeline by Phase of Clinical Development, 2011
- Figure 25: Gallbladder Cancer Therapeutics - Clinical Pipeline by Mechanism Of Action, 2011
- Figure 26: Gallbladder Cancer Therapeutics - Technology Trends Analytical Framework, 2011
- Figure 27: Gallbladder Cancer Therapeutics - Technology Trends Analytical Framework - Description, 2011
- Figure 28: Gallbladder Cancer Therapeutics - Clinical Trials by Country, 2011
- Figure 29: Gallbladder Cancer Therapeutics - Clinical Trials by Phase, 2011
- Figure 30: Gallbladder Cancer Therapeutics - Clinical Trials by Status, 2011
- Figure 31: Gallbladder Cancer Therapeutics - Clinical Trials by Overall Sponsors, 2011
- Figure 32: Gallbladder Cancer Therapeutics - Clinical trials by Prominent Sponsors, 2011
- Figure 33: Gallbladder Cancer Therapeutics Clinical Trial - Company Sponsors by Phase, 2011
- Figure 34: Gallbladder Cancer Therapeutics, Strategic Assessment, 2011
- Figure 35: Gallbladder Cancer Therapeutics Market - Clinical Pipeline by Company , 2011
- Figure 36: GlobalData Market Forecasting Model
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|